Evidence map›Paper›PMID 37248741›Full record

ArticleTransfusion2023

Novel computational methods on electronic health record yields new estimates of transfusion-associated circulatory overload in populations enriched with high-risk patients.

Michelle Wang, Gregory M Goldgof, Ayan Patel, Barbee Whitaker, Artur Belov, Brian Chan, Evan Phelps, Benjamin Rubin, Steven Anderson, Atul J Butte

Open access · hybridAbstract read
In one paragraph

Article in Transfusion, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Michelle WangBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-3207-1490
Gregory M GoldgofBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, California, USA.
Ayan PatelBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, California, USA.
Barbee WhitakerOffice of Biostatistics & Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration (FDA), Silver Spring, Maryland, USA.ORCID 0000-0002-6311-6268
Artur BelovOffice of Biostatistics & Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration (FDA), Silver Spring, Maryland, USA.ORCID 0000-0001-6848-1224
Brian ChanBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, California, USA.
Evan PhelpsBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, California, USA.
Benjamin RubinBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, California, USA.
Steven AndersonOffice of Biostatistics & Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Atul J ButteBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-7433-2740
University of California, San Francisco · USCenter for Biologics Evaluation and Research · US

Funding

Clinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1M
UCSF-Stanford Center of Excellence in Regulatory Science and InnovationU01FD005978 · FDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALTMAN, RUSS BIAGIO, GIACOMINI, KATHLEEN M · 2016 to 2025
$34.5M
PHARMACEUTICAL SCIENCES AND PHARMACOGENOMICST32GM007175 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, KROETZ, DEANNA L · 1985 to 2021
$7.1M
Enhancing Resident Investigation and Career Advancement in Cardiovascular and Pulmonary ScienceR38HL143581 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIBBINS-DOMINGO, KIRSTEN, HUANG, ALISON · 2018 to 2021
$1.4M
Deep learning tools for the automated analysis of hematopathology whole slide images and the development of prognostic algorithms for hematopoietic stem cell transplant recipientsK38HL159128 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOLDGOF, GREGORY MARK · 2021 to 2021
$119k
FDA HHS U01 FD005978NCATS NIH HHS UL1 TR001872NHLBI NIH HHS K38 HL159128NHLBI NIH HHS R38 HL143581NIGMS NIH HHS T32 GM007175
6 · The paper itself

Abstract

backgroundTransfusion-associated circulatory overload (TACO) is a severe adverse reaction (AR) contributing to the leading cause of mortality associated with transfusions. As strategies to mitigate TACO have been increasingly adopted, an update of prevalence rates and risk factors associated with TACO using the growing sources of electronic health record (EHR) data can help understand transfusion safety. STUDY DESIGN AND

methodsThis retrospective study aimed to provide a timely and reproducible assessment of prevalence rates and risk factors associated with TACO. Novel natural language processing methods, now made publicly available on GitHub, were developed to extract ARs from 3178 transfusion reaction reports. Other patient-level data were extracted computationally from UCSF EHR between 2012 and 2022. The odds ratio estimates of risk factors were calculated using a multivariate logistic regression analysis with case-to-control matched on sex and age at a ratio of 1:5.

resultsA total of 56,208 patients received transfusions (total 573,533 units) at UCSF during the study period and 102 patients developed TACO. The prevalence of TACO was estimated to be 0.2% per patient (102/total 56,208). Patients with a history of coagulopathy (OR, 1.36; 95% CI, 1.04-1.79) and transplant (OR, 1.99; 95% CI, 1.48-2.68) were associated with increased odds of TACO. DISCUSSION: While TACO is a serious AR, events remained rare, even in populations enriched with high-risk patients. Novel computational methods can be used to find and continually surveil for transfusion ARs. Results suggest that patients with history or presence of coagulopathy and organ transplant should be carefully monitored to mitigate potential risks of TACO.

Indexed as

Electronic Health RecordsTransfusion ReactionBlood TransfusionHumansRetrospective StudiesRisk FactorsHealth research methodologyTransfusion complications-non infectious

Identifiers

PMID37248741
PMCPMC10449535
OpenAlexW4378713625

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.